LifeVantage Corp. (LFVN), Tuesday announced promising results of an in vitro study, investigating the combined effects of its upcoming two-product system on activating GLP-1 production, a critical hormone in weight management and glucose regulation.
The study demonstrated an increase in GLP-1 production and a synergistic activation of the key genes responsible for its synthesis and regulation.
"We are excited by the scientific evidence supporting the claims of our new GLP-1 system and we are thrilled to be able to introduce the this system beginning in October," said Steve Fife, President and CEO of the company.
Currently, LifeVantage's stock is trading at $9.26, up 8.56 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.